comprehensive -WSS

comprehensive

author：knowledge 2025-10-06 06:42:49 - browse：84326

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： House panel takes first step toward fixing drug shortages

leisure time

WSS

Eli Lilly CEO gives to Mike Pence presidential super PAC

CDC backtracks, saying fully vaccinated people can go maskless indoors

FDA official pushes for dedicated emerging pathogens team

PBMs drew scrutiny in House hearing — and so did pharma

AbbVie dramatically boosts its spending on lobbying

David Liu startup to focus on CRISPR delivery

hotspot

comprehensive

leisure time

How to save PrEP access — and even expand it

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

BioMarin wins approval for gene therapy to treat hemophilia A

The unintended consequences of overturning Roe v. Wade

Wildfire smoke exposes gaps in outdoor worker protections

Akili changes sales model for its ADHD video game treatment

Medical records are filled with copy

Chamber of Commerce, DOJ clash in court over drug prices

Trump demands the U.S. pay no more for drugs than other countries … again

White House launches permanent pandemic office

knowledge

FDA weighs limits of animal data in assessing artificial wombs

Senate bill would ban some hospital facility fees

Fed up with FDA, ALS advocates consider a take

Organ transplantation is at a crossroads. Major reform is needed

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Fed up with FDA, ALS advocates consider a take

leisure time

Wikipedia

hotspot

entertainment